4.5 Article

Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1

期刊

NEUROBIOLOGY OF AGING
卷 34, 期 1, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2012.07.017

关键词

Amyotrophic lateral sclerosis; Genome-wide association study; Age at onset

资金

  1. ALS Association
  2. Packard Center for ALS Research atHopkins
  3. Microsoft Research
  4. NIA [Z01-AG000949-02]
  5. NINDS
  6. European Community [259867]
  7. National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London
  8. Maudsley NHS Foundation Trust
  9. King's College, London
  10. Medical Research Council
  11. Motor Neuron Disease Association (UK)
  12. American ALS Association
  13. Heaton-Ellis Trust
  14. Psychiatry Research Trust
  15. Muscular Dystrophy Association (United States)
  16. Irish Motor Neurone Disease Research Foundation
  17. Health Research Board of Ireland
  18. Irish Institute of Clinical Neuroscience Travel Award
  19. Les Turner ALS Foundation
  20. National Institute of Neurological Disorders and Stroke [NS050641, ES014469]
  21. ALS Therapy Alliance (CVS pharmacies)
  22. Vena E. Schaff ALS Research Fund
  23. Harold Post Research Professorship
  24. Herbert and Florence C. Wenske Foundation
  25. David C. Asselin, M. D. Memorial Fund
  26. Help America Foundation
  27. Ride for Life
  28. Federazione Italiana Giuoco Calcio
  29. Fondazione Vialli e Mauro per la Sclerosi Laterale Amiotrofica onlus
  30. Ministero della Salute
  31. Regione Piemonte
  32. Myasthenia Gravis Foundation
  33. FIGC
  34. AriSLA
  35. Rudolf Magnus Institute Young Talent Fellowship
  36. Swedish Brain Power
  37. Bertil Hallsten Brain Research Foundation
  38. Swedish Science Council
  39. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER
  40. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014469] Funding Source: NIH RePORTER
  41. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050641, R01NS073873] Funding Source: NIH RePORTER
  42. NATIONAL INSTITUTE ON AGING [ZIAAG000933, ZIAAG000949, Z01AG000949] Funding Source: NIH RePORTER
  43. Medical Research Council [G0500289, G0600974, MC_G1000733, G0900635, G0500289B, G0900688, G1100695] Funding Source: researchfish
  44. MRC [G0900688, MC_G1000733, G0600974, G0900635, G1100695, G0500289] Funding Source: UKRI

向作者/读者索取更多资源

Amyotrophic lateral sclerosis (ALS) is the third most common adult-onset neurodegenerative disease. Individuals with ALS rapidly progress to paralysis and die from respiratory failure within 3 to 5 years after symptom onset. Epidemiological factors explain only a modest amount of the risk for ALS. However, there is growing evidence of a strong genetic component to both familial and sporadic ALS risk. The International Consortium on Amyotrophic Lateral Sclerosis Genetics was established to bring together existing genome-wide association cohorts and identify sporadic ALS susceptibility and age at symptom onset loci. Here, we report the results of a meta-analysis of the International Consortium on Amyotrophic Lateral Sclerosis Genetics genome-wide association samples, consisting of 4243 ALS cases and 5112 controls from 13 European ancestry cohorts from across the United States and Europe. Eight genomic regions provided evidence of association with ALS, including 9p21.2 (rs3849942, odds ratio [OR] = 1.21; p = 4.41 x 10(-7)), 17p11.2 (rs7477, OR = 1.30; p = 2.89 x 10(-7)), and 19p13 (rs12608932, OR = 1.37, p = 1.29 x 10(-7)). Six genomic regions were associated with age at onset of ALS. The strongest evidence for an age of onset locus was observed at 1p34.1, with comparable evidence at rs3011225 (R-partial(2) = 0.0061; p = 6.59 x 10(-8)) and rs803675 (R-partial(2) = 0.0060; p = 6.96 x 10(-8)). These associations were consistent across all 13 cohorts. For rs3011225, individuals with at least 1 copy of the minor allele had an earlier average age of onset of over 2 years. Identifying the underlying pathways influencing susceptibility to and age at onset of ALS may provide insight into the pathogenic mechanisms and motivate new pharmacologic targets for this fatal neurodegenerative disease. (C) 2013 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据